<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505489</url>
  </required_header>
  <id_info>
    <org_study_id>MAN-2018</org_study_id>
    <nct_id>NCT03505489</nct_id>
  </id_info>
  <brief_title>The Effect of Deep Inhalation on Mannitol Responsiveness</brief_title>
  <official_title>The Effect of Deep Inhalation on Mannitol Responsiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess how the inhalation technique used (deep inhalations versus tidal
      breathing) influences the results of a mannitol challenge test and a methacholine challenge
      test, if at all.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will look at airway responsiveness to inhaled methacholine and mannitol
      administered with and without deep inhalation. This study will also investigate the role of
      airway inflammation on these responses, using sputum differential cell counts and fractional
      exhaled nitric oxide.

      This is a single center, open label, randomized study. Individuals with stable asthma will be
      eligible for enrollment. The study will consist of two parts, screening and testing.

      Part 1: Screening

      Participants will undergo consent procedures and assessments of fractional exhaled nitric
      oxide levels, airway responsiveness to methacholine and sputum induction. If participants
      show airway responsiveness to methacholine (i.e. methacholine PC20 16mg/mL), they will be
      scheduled to undergo the testing part of the study.

      Part 2: Testing

      Participants will be randomized to undergo two methacholine or two mannitol challenges.
      Further randomization will occur with respect to whether the standard challenge method or the
      modified challenge method is performed first.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of deep inhalation (versus tidal breathing) on mannitol provocative dose causing a 15% fall in forced expiratory volume in one second (FEV1)</measure>
    <time_frame>24 hours between mannitol challenges</time_frame>
    <description>Shift in mannitol provocative dose causing a 15% fall in forced expiratory volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of airway inflammation on methacholine and mannitol challenge results-fractional exhaled nitric oxide</measure>
    <time_frame>up to 2 weeks, from baseline to end of study</time_frame>
    <description>Collection of fractional exhaled nitric oxide at screening - analysis of resulting measurement indicative of degree of baseline airway inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of airway inflammation on methacholine and mannitol challenge results-sputum</measure>
    <time_frame>up to 2 weeks, from baseline to end of study</time_frame>
    <description>Collection of sputum at screening - analysis for differential cell counts indicative of degree of baseline airway inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of deep inhalation (versus tidal breathing) on methacholine provocative</measure>
    <time_frame>24 hours between methacholine challenges</time_frame>
    <description>Shift in methacholine provocative dose causing a 20% fall in forced expiratory volume</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Mannitol challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mannitol challenge w/ TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methacholine challenge w/ DI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methacholine challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Deep inhalation technique</intervention_name>
    <description>Use of deep inhalations for administration of inhalant</description>
    <arm_group_label>Mannitol challenge</arm_group_label>
    <arm_group_label>Methacholine challenge w/ DI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tidal breathing technique</intervention_name>
    <description>Use of tidal breathing for administration of inhalant</description>
    <arm_group_label>Mannitol challenge w/ TBI</arm_group_label>
    <arm_group_label>Methacholine challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methacholine</intervention_name>
    <description>Methacholine direct bronchoconstrictor used for bronchoprovocation challenge</description>
    <arm_group_label>Methacholine challenge w/ DI</arm_group_label>
    <arm_group_label>Methacholine challenge</arm_group_label>
    <other_name>Provocholine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge</description>
    <arm_group_label>Mannitol challenge</arm_group_label>
    <arm_group_label>Mannitol challenge w/ TBI</arm_group_label>
    <other_name>Aridol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  men and women between 18 and 75 years of age

          -  FEV1 at first measurement of greater than or equal to 65% predicted

          -  methacholine provocative concentration causing a 20% in FEV1 at screening that is less
             than or equal to 16mg/ml

          -  generally good health

          -  stable asthma

        Exclusion Criteria:

          -  respiratory infection within 4 weeks of screening visit

          -  worsening of asthma within 4 weeks of screening visit

          -  lung disease other than asthma

          -  significant medical comorbidity

          -  current smoker or ex-smoker with significant smoking history

          -  currently pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Don Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Don Cockcroft, MD</last_name>
    <phone>306-844-1446</phone>
    <email>don.cockcroft@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asthma Research Lab - University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Don Cockcroft, MD</last_name>
      <phone>306-844-1446</phone>
      <email>don.cockcroft@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Beth Davis, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Mannitol</keyword>
  <keyword>Methacholine</keyword>
  <keyword>Deep inhalation</keyword>
  <keyword>Tidal breathing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

